CClinicalTrials.gg
Not yet recruitingNCT07271277IMAHANCHEUpdated Aug 20, 2026

3D MRI Assessment of Femoroacetabular Impingement in Patients With ACL Rupture - Exploratory Study

An interventional study of 3D MRI in Femoroacetabular Impingement, sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by GCS Ramsay Santé pour l'Enseignement et la Recherche · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Anterior cruciate ligament (ACL) tears are among the most common sports injuries. Numerous studies have shown that reduced hip rotation may play a role in ACL tears. The same question may also arise for hip injuries such as femoroacetabular impingement (FAI).

This research is based on the hypothesis that there is a relationship between FAI and ACL injury. In this context, 3D MRI of the hip would provide morphological details of the hip that are not currently available with other imaging techniques, thereby enabling early identification of FAI. This is the reason why this research has been initiated.

Read the detailed description

Anterior cruciate ligament (ACL) tears are among the most common sports injuries. It is estimated that approximately 150,000 ACL reconstructions are performed each year in the United States. Numerous studies have shown that reduced hip rotation may play a role in ACL tears. The same question may also arise for hip injuries such as femoroacetabular impingement (FAI).

This research is based on the hypothesis that there is a relationship between FAI and ACL injury. In this context, 3D MRI of the hip would provide morphological details of the hip that are not currently available with other imaging techniques, thereby enabling early identification of FAI. This is the reason why this research has been initiated.

02

Conditions studied

  • Femoroacetabular Impingement

Keywords

  • femoroacetabular impingement
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patient, male or female, aged 18 years or older
  • Patient with a primary complete ACL rupture
  • Patient affiliated with or covered by a social security scheme
  • Patient who speaks French and has signed an informed consent form

Exclusion criteria

Exclusion Criteria:

  • Patient with multi-ligament injury
  • Patients with a history of hip fracture
  • Patients with a history of hip surgery
  • Patients with a contraindication to MRI
  • Protected individuals: adults under guardianship, curatorship or other legal protection, deprived of their liberty by judicial or administrative decision
  • Pregnant or breastfeeding women
04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    FAI arm

    FAI arm involves patients with ACL rupture. A 3D MRI scan of both hips of theses patients will be performed.

    Other: 3D MRI

Interventions

  • Other3D MRI

    Intervention consists of performing a 3D MRI scan of both hips using a T1 sequence.

05

What researchers measure

Primary outcomes

  1. FAI (femoroacetabular impingement) prevalence

    Prevalence of femoroacetabular impingement will be expressed as %. It will be measured on the injured knee side (i.e., ACL rupture) and on the healthy knee side (i.e., uninjured).

    Time frame: Day 1

06

Study locations

1 site
  • Hôpital Privé Jean Mermoz
    Lyon, France 69008, France
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07271277
Lead sponsor
GCS Ramsay Santé pour l'Enseignement et la Recherche
Responsible party
Sponsor
First posted
Dec 9, 2025
Start date
Oct 1, 2026 (estimated)
Primary completion
Jan 31, 2028 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Aug 20, 2026

Study contacts

Bertrand SONNERY-COTTET, MD
Contact
sonnerycottet@aol.com
+33 4 37 53 00 22

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion